Genta Incorporated announced that it has initiated a confirmatory Phase 2b trial of tesetaxel in patients with advanced gastric cancer. This trial is designed to confirm the efficacy results observed in a preliminary Phase 2a study of tesetaxel as second-line treatment of gastric cancer patients. It will enroll patients who have progressed on a single first-line chemotherapy regimen. Endpoints of the new Phase 2b study include response rate, durable response, disease control, progression-free survival, and safety.
Tesetaxel is a novel, orally absorbed, semi-synthetic taxane. Tesetaxel was developed with a goal of maintaining the high antitumor activity of the taxane drug class while eliminating infusion reactions associated with intravenous taxanes (eg, paclitaxel and docetaxel), reducing neuropathy, and increasing patient convenience.
For more information call (908) 286-9800 or visit www.genta.com.